Keytruda (pembrolizumab) is an immunotherapy drug used to treat various types of cancer
Keytruda (pembrolizumab) is an immunotherapy drug used to treat various types of cancer. It is a monoclonal antibody that works by targeting the PD-1 (programmed death receptor-1) pathway, helping the immune system recognize and attack cancer cells.
Uses of Keytruda
Keytruda is FDA-approved for treating:
- Non-small cell lung cancer (NSCLC)
- Melanoma
- Head and neck squamous cell carcinoma
- Hodgkin lymphoma
- Bladder cancer
- Colorectal cancer (with microsatellite instability-high or mismatch repair deficiency)
- Cervical cancer
- Other cancers with specific genetic markers
How It Works
Cancer cells can evade immune system attacks by binding to PD-1 on T cells, effectively "turning off" the immune response. Keytruda blocks PD-1, allowing the immune system to detect and destroy cancer cells more effectively.
Administration & Dosage
- Given as an intravenous (IV) infusion
- Typically administered every 3 to 6 weeks, depending on the condition
Common Side Effects
- Fatigue
- Nausea
- Rash
- Diarrhea
- Cough
- Immune-related side effects (e.g., inflammation of the lungs, liver, intestines, or thyroid)
Cost & Availability
Keytruda is an expensive drug, often costing thousands of dollars per dose. Insurance coverage, manufacturer assistance programs, and clinical trials may help reduce costs.
Would you like information on a specific aspect, such as side effects, clinical trials, or pricing?
Comments